I
n patients with an acute myocardial infarction (AMI), depressive symptoms are associated with worse mortality outcomes, 1 worse morbidity outcomes, 2 worse quality of life outcomes, 3 and greater healthcare costs. 4 Calls have been issued for depression to be recognized as a risk marker 5 and patients with AMI to be regularly screened for depression. 6 In fact, the American Heart Association recently recognized depression as a risk factor for poor prognosis among patients with AMI, based on their systematic literature review of depression's observational association with all-cause mortality, cardiac mortality, and composite end point in patients after an MI. 7 Clinicians, confronting this current observational evidence base and set of recommendations, are left to use any of the existing depression identification or treatments for patients with AMI, leading to practice variation and increasing health disparities in care for this prevalent clinical comorbidity. 8 On reading about the large, international, multidecade weight of observational evidence supporting the conjecture that depression portends ill for patients with AMI, many queries may cross one's mind. One logical question to ask, as an interested clinician or scholar, is whether treating depression in these patients would improve these many medical outcomes. A scholar or clinician with more circumspect horizons might simply ask whether treating depression actually improves depressive symptoms in these patients. The way to address these questions, and of course all the subsidiary questions that would then arise, is through the conduct of large, generalizable randomized clinical trials. Some of those subsidiary questions, to name a few, include: What dose and duration of depression treatment is most useful? Is pharmaceutical or behavioral counseling treatment superior? When in the course of MI recovery should depression treatment be offered and to whom?
Some have argued that because no trial evidence indicates that treating depression alters the poor prognosis associated with depression, depression is in fact more analogous to high-density lipoprotein or C-reactive protein as a marker of poor prognosis but not as a target for active intervention. 9 Additionally, a systematic review of the existing small trials on depression screening and treatment in depressed patients with AMI suggested few clinical benefits of either screening or treatment. 10 Of course these trials did not have statistical power to appropriately test these effects. An updated systematic review's main conclusion was that little trial evidenceexists in this area. 11 While waiting for the definitive trials that would address these important clinical questions, we arrive at the most current published articles.
In this issue of Circulation, Smolderen and colleagues 12, 13 have creatively sought to find indirect evidence of depression treatment benefit from 2 different, large observational registries. These articles report on the association between receiving pharmaceutical depression treatment and improved patient-reported health status outcomes from 1 registry and differential 1-year mortality outcomes in the other. In examining sex differences in depression treatment rates in the observational VIRGO study (Variation in Recovery: Role of Gender on Outcomes of Young AMI Patients) (n=3324), 36.6% of women and 19.7% of men reported depressive symptoms consistent with a depressive disorder.
14 It is important to note that half of these patients (57.8%) were not being treated for depression, as defined by receiving an antidepressant prescription or receiving counseling within 1 month of discharge. As found elsewhere, 15 the authors report that the majority of untreated depressed patients with MI nonetheless recover, suggesting that some portion of patients with AMI have only transient depressive symptoms. Like others, the authors found that those patients with persistent depressive symptoms after an MI have the worse prognosis-in this case, more angina and worse disease quality of life. 16 In the second article, the TRIUMPH registry (Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status) (n=4062) was used to compare 1-year mortality outcomes among untreated depressed patients with AMI (n=528), treated depressed patients with AMI (n=231), and nondepressed patients with AMI (n=3303). When adjusting for numerous clinical and demographic factors, the treated depressed and nondepressed patients had similar 1-year mortality rates; the untreated depressed patients had an ≈2-fold worse mortality rates compared with these two groups.
What can we conclude from these findings? These observational studies provide intriguing signals that conventional depression treatment, primarily pharmaceutical in nature, may aid these patients with their depression as well as health quality of life and survival. Observational data, frustratingly, of course leave many unanswered questions. Is the type of healthcare setting that detects and treats depression in patients with AMI a higher quality institution than the type of care setting that does not? Is it the type of patient who is identified as depressed that benefits, and are these types of patients fundamentally different from those who are not so identified? Are these patients perhaps from a higher socioeconomic background or education achievement level, or do they perhaps have private rather than public or no health insurance? Do they have regular primary care interactions, such that a healthcare professional could notice deterioration in their mental quality of life and decide to intervene?
Unfortunately, we can only draw a few definitive conclusions draw from these 2 large studies: depressive symptoms are highly prevalent; 17 depressive symptoms are, for too many patients, persistent; and depressive symptoms are rarely detected and treated in this large patient population. Other than these conclusions, all others are somewhat suspect because conclusions from observational data are vulnerable to a multitude of biasesall leading to the inevitable discussion that we cannot provide any reasonable evidence-based recommendation about the treatment of depression in patients with MI without data from large randomized clinical trials. Thus, we return, despite the somewhat circuitous route we have taken, to "Godot." We wait for the definitive trials that will answer these urgent clinical and public health issues. While we wait, we discuss, and our patients suffer.
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